{"id":"W3083222874","doi":"10.3747/co.27.5985","title":"Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; Bristol-Myers Squibb (Canada); McMaster University; London Health Sciences Centre","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Internal medicine; Expanded access; Adverse effect; Cohort; Melanoma; Population; Oncology; Hazard ratio; Confidence interval; Surgery; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008730885,0.0002968133,0.0002228645,0.000351831,0.001320648,0.0004032823,0.0005554018,0.0002103393,0.004041715],"category_scores_gemma":[0.0009227875,0.0001185926,0.000358732,0.0007408575,0.0002469683,0.0001640413,0.0004989949,0.0004890626,0.0005262784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006774803,"about_ca_system_score_gemma":0.01579576,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.6714644,"about_ca_topic_score_gemma":0.834797,"domain_scores_codex":[0.9994481,0.00007022679,0.00001561039,0.00008278448,0.0002363403,0.0001468261],"domain_scores_gemma":[0.9988987,0.00004442378,0.0001464352,0.00008177987,0.0003898148,0.0004387368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01558147,0.002843372,0.7371032,0.0003577316,0.000463201,0.0005977295,0.0003832587,0.001638912,0.006113967,0.0008821599,0.06392241,0.1701125],"study_design_scores_gemma":[0.003651168,0.004385037,0.9106668,0.0001057684,0.0003565941,0.0007135811,0.000187426,0.001314716,0.001273891,0.0001874015,0.07712381,0.00003391301],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9560384,0.002622324,0.0008848728,0.001281475,0.0001322732,0.00159619,0.01688546,0.000129671,0.02042921],"genre_scores_gemma":[0.9763579,0.001309859,0.001490631,0.0009974465,0.00008491339,0.0004943665,0.01207853,0.00002394567,0.007162303],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6714644,"threshold_uncertainty_score":0.6609407,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08545878039336403,"score_gpt":0.4157891680202777,"score_spread":0.3303303876269137,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}